Several implications deserve attention
Removal of Two Social Drivers of Health Measures From the Hospital OQR, REHQR, and ASCQR Programs Beginning With the CY 2025 Reporting Period In the CY 2026 OPPS/ASC proposed rule (90 FR 33756), we proposed to remove two social drivers of health (SDOH) process measures from the Hospital OQR, REHQR, and ASCQR Programs beginning with the CY 2025 reporting period: Screening for Social Drivers of Health (adopted at 89 FR 94381 through 94398) and Screen Positive Rate for Social Drivers of Health (adopted at 89 FR 94398 through 94403), for which the CY 2025 reporting period would be voluntary, and mandatory reporting would begin with the CY 2026 reporting period/CY 2028 payment or program determination
However, its essential to disclose all current medications, supplements, and treatments to our physicians during your consultation
The April 2026 FDA action removes them from the Category 2 restricted compounding list effective April 23, 2026, and the FDAs Pharmacy Compounding Advisory Committee will review their compounding eligibility under 503A at its July 23-24, 2026 meeting
I had a intramuscular hydroxocobalamin (neo cytamen) injection in
Healthcare providers should adopt stringent evaluation procedures when considering the use of such compounds
